FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  REINHARDT MAX					2. Issuer Name <b>and</b> Ticker or Trading Symbol Pacira BioSciences, Inc. [ PCRX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify						
	CIRA BIOS	CIENCES, INC.			04/	3. Date of Earliest Transaction (Month/Day/Year) 04/21/2022										below) t, Rest of World			
5401 WEST KENNEDY BOULEVARD, SUITE 890 (Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person					
TAMPA (City)	FI (Si		33609 (Zip)		-										Form filed by More than One Reporting Person				
(Oity)		,		n Davis		ative Securities Acquired, Disposed of, or Beneficially Owned													
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day				action	tion 2A. Deemed Execution Date,		3. 4. Securiti Transaction Code (Instr.		it, or Beneficia ies Acquired (A) or Of (D) (Instr. 3, 4 and		5. Amou Securition Benefici	nt of es ally Following	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	ion(s)			(Instr. 4)	
Common Stock 04/21/2					L/ <b>202</b> 2	2022		M <sup>(1)</sup>		12,500	) A	\$42.5	4 39	39,474		D			
Common Stock 04/21/2					L/ <b>202</b> 2	2022		S <sup>(1)</sup>		9,824 <sup>(2)</sup> D \$7		\$73.2	54 29	4 29,650		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dar if any (Month/Day/Yo	Date,	Date, Transac Code (In				6. Date Exercisal Expiration Date (Month/Day/Year)		te	of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	illy	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
					Code	V	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$42.54	04/21/2022			М			12,500	(3)		07/02/2029	Common Stock	12,500	\$0.00	100,00	0	D		

## **Explanation of Responses:**

- 1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- 2. Represents shares sold by the reporting person to cover the (i) exercise price of stock options and (ii) tax obligations due upon the exercise of such stock options.
- 3. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

## Remarks:

/s/ Kristen Williams, Attorneyin-Fact

04/25/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.